

Data Sharing Statement

Boulware DR, Lindsell CJ, Stewart TG, et al. Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19. *N Engl J Med*. DOI: 10.1056/NEJMoa2209421.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Complete de-identified patient data set
Additional information about data	—
How or where can the data be obtained?	The data can be obtained from a public repository.
When will data availability begin?	Data will be deposited in a public repository when the platform trial has concluded.
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	Prior to deposition of the data in a public repository which will occur when the platform trial has concluded, persons may request the data by submitting a proposal. If the data can be used for the proposed purpose and it is consistent with the informed consent, then the data will be released under a Data Use Agreement.
For what type of analysis or purpose?	For any purpose consistent with consent provided by participants and for which the data are fit.
By what mechanism?	—
Any other restrictions?	—
Additional information	—

This statement was posted on September 21, 2023, at NEJM.org.